A study of JMKX005425 for certain advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called JMKX005425 for people with advanced solid tumors that have a specific genetic feature called MSI-H or dMMR. If you have this feature and your cancer has not responded to other treatments, this study may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must be tested and show a specific genetic feature called MSI-H or dMMR.
- You must have at least one tumor that can be measured on scans.
- You should expect to live at least 12 more weeks.
- Your organs must be working well enough, including your kidneys, liver, and bone marrow.
- Any side effects from previous cancer treatments must have improved enough.
- You cannot have had another cancer in the last 3 years (except some treated earlier ones).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, MK-6204, in people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
This Phase 2 trial tests KN035 in people with advanced or spread-out tumors that have specific genetic markers (MSI-H or dMMR). If you qualify, the study team will look at how well the drug works and how it affects side effects in that group.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This Phase 1 trial tests KM602, a new study treatment, in people with advanced solid tumors like melanoma or non-small cell lung cancer that have progressed after standard treatments. If you qualify, the goal is to see how the drug works and how safe it is in early research.
This trial tests a new drug, GSK5460025, alone or with other cancer treatments, for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help those whose cancer has a specific genetic feature (dMMR or MSI-H) or who have not responded to standard treatments.
This trial tests a new targeted therapy, JMKX001899, combined with other treatments for advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It aims to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.